Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
this meeting stated in the article 'New Covid-19 treatment for patients with diabetes shows early promise'
the team’s work was recognised at a reception at 10 Downing Street attended by Professor Martin. The reception was held to celebrate the UK-United Arab Emirates prosperity and innovation partnership, as the UAE’s sovereign wealth fund contributed to the trial’s funding. https://www.ucl.ac.uk/news/2021/sep/new-covid-19-treatment-patients-diabetes-shows-early-promise
Below is the content of 14th December Vela PR: SGSC are undertaking commercial discussions with potential licensees and partners and examining options for the next stage of the development and approval process. The finalisation of the CSR formally marks the end of the ARCADIA trial.
Details of Vela's economic interest in the potential commercialisation of the Asset, the Asset and the ARCADIA trial were included in the announcement published by Vela on 20 October 2020.
James Normand, Director of Vela, commented: "The board of Vela is delighted to be informed of this significant development in what is the Company's most material investment. We note that SGSC is now moving forward with the proposed commercialisation of the AZ1656 drug and we look forward to positive news on this process in the near future."
Among China's 1.4 billion population, estimated 200-300m diabetics, 500m suffer from cardio vascular related conditions, FF is a great product to alleviate the risks associated with the above mentioned chronicle conditions. With By-Health scientific and research director is the original FF technology developer coming out of Aberddeen university, and the Chinese government policy shift and By-Health huge research investment so far, FF China market sale revenue figure can be exponential . Judging recent posting indicated Amazon and H&B online stores ran out of FF, hope the half yearly revenue figure will be substancial.
This article is written by BH research institute and is an important signal that By Health will make next move and long awaited push for marketing series of FruitFlow related products in China market. There will have more such scientifically informative articles written to prepare the public for products launches. Very positive sign indeed!
Well done to spot this switch as MEDiSTRAVA Consulting is full of successes for advising FDA approvals, very important signal to be noted. Come on Sareum, show the world your true colour - one of the best science of novel drug development.
It's a simple math 6,428,571 (warrants) * 5 = the shares issued (32,142,855) , £180k * 5 = the £900k funds raised from the HNWI on 1st June. This demonstrates further confidence and commitment from HNWI to the science and imminent breakthrough on Covid-19 treatment and other pipeline of Sareum therapeutics for Autoimmune Diseases and Cancer which are fast approaching clinical.
After nearly 5 years since signing the deal with By-Health and their alleged series research studies, there are still no any news to show efforts by By-Health to register any FruitFlow based products in China market. It seems to me that By-Health used the partnership deal, the scientific credentials and series research studies as a gimmick to advance their own purpose of tripling By-Health market capitalisation to current 50 billion Yuan.
As the 19th July timeline for total lifting pandemic preventative measures in UK, this means we all will swim half naked in the sea of pandemic, some will have pants/bikinis on, some with life jackets on as well. So I suggest everyone should copy and paste the below message to multiple channels to highlight the potential of one more self saving measures in the form a daily food supplement tablet which might give one little extra strength to swim out of the sea of pandemic.
Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow® be
used as an antiplatelet regime?"
https://www.provexis.com/wp-content/uploads/2021/04/Platelet-hyperactivity-in-COVID-19-Can-the-tomato-extract-Fruitflow-be-used-as-an-antiplatelet-regime-04-Jan-21.pdf
"The new coronavirus causes excessive activation of platelets, and water-soluble tomato extract may relieve it"
Huge market potential if By-Health Fruitflow related series products approved for marketing in China and globally
https://m.binh.cn/minio/resources/upload/20201204/409be98c9ad445bc89c1925734a03bea.pdf
The Motley Fool's article requires proof reading for some basic knowledge and facts as following:
1. IBD indication is definitely not irritable bowel disease (IBD) as stated by the article but rather Inflammatory bowel disease(IBD) which are two different chronicle conditions with quite different causes, the disease severeness and genetic cause of Inflammatory bowel disease(IBD) has categorised it as an Autoimmune disease, irritable bowel syndrome (IBS) is not.
2. 'the success of the Sareum share price is due to the Covid-19-related hyping of biotech stocks' is rather a blindfolded statement without any merit or scientific consideration, there are strong science and research data to support Sareum's SDC-1801 as a possible therapeutic option to treat cytokine storm in severe Covid-19 disease. Also other projects SDC-1802 for cancer and CHK1 inhibitor SRA737 cancer treatment to Sierra Oncology are proof that Sareum share price success is not at all based on the Covid-19-related hyping of biotech stocks, but based on solid science and several fronts projects progress.
3. Regarding further funding for clinical trials, one important element is the Agile clinical trial support from the government, if the UKRI sponsored SDC-1801 study can yield positive result, this will definitely qualify SDC-1801 for clinical trial funding of Agile.
Finally, I agree the generalised statement that 'penny stocks are notoriously risky investments', but need to see the science and the huge reward potential - 'share price is up 1,160% from its 52-week low'.
Since the below press release put up last December, there is no any further news on the progress, the board should inform the PIs timely on the progress, if any of the planned options go ahead, judging the blood circulation related cardio-vascular disease sufferers huge numbers in China, this company will become profitable overnight and LT share holders will expect a dividend payment.
'The Company is working closely with By-Health Co., Ltd, a £5bn listed Chinese dietary supplement business, to support the planned launch of some Fruitflow based products in the Chinese market. The planned launch is progressing well with potential sales volumes remaining at a significant multiple of existing Fruitflow sales.
By-Health has made a significant investment in nine separate clinical studies in China, at its sole expense, in support of the Fruitflow based products which it plans to launch in China. The five studies which have been completed by By-Health showed excellent results in use for Fruitflow, and provide strong evidence for By-Health in its regulatory submissions for Fruitflow.
If a successful blue cap health claim is achieved for Fruitflow in China it would currently be expected to result in some significant recurring orders for Fruitflow, at a multiple of current total sales values.'
Any learned statistician can analyse the below link Scotland Covid-19 trend to predict the STAR Covid-19 trial potential.
https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-19DailyDashboard_15960160643010/Overview
Evgen will have no cash call and no dilution until 2023, that stage the non-pharm deal with JV Life will have stream of milestones and royalty cash payments kicking in, difficult to understand why the share price is kept so low.
On 31 March 2021, the Group had cash and cash equivalents, including short-term investments and cash on deposit, of £11.59 million.
The Directors have prepared detailed financial forecasts and cash flows looking beyond 12 months from the date of the approval of these financial statements. In developing these forecasts, the Directors have made assumptions based upon their view of the current and future economic conditions that will prevail over the forecast period.
The Directors estimate that the cash held by the Group together with known receivables will be sufficient to support the current level of activities to the middle of 2023. They have therefore prepared the financial statements on a going concern basis.
and share price will be depressed further